Qualigen Therapeutics Trading Down 6.3 %
Shares of Qualigen Therapeutics stock opened at $0.20 on Monday. The stock has a fifty day simple moving average of $0.26 and a 200 day simple moving average of $0.41. Qualigen Therapeutics has a 12-month low of $0.18 and a 12-month high of $3.12.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Qualigen Therapeutics stock. Ground Swell Capital LLC acquired a new stake in Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Rating) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 43,251 shares of the company’s stock, valued at approximately $29,000. Ground Swell Capital LLC owned 0.12% of Qualigen Therapeutics at the end of the most recent reporting period. 14.95% of the stock is owned by institutional investors.
Qualigen Therapeutics Company Profile
Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood.
- Get a free copy of the StockNews.com research report on Qualigen Therapeutics (QLGN)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Is Ardelyx is A Buy After Slip in Early 2022
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.